Early and late effects of electroconvulsive therapy associated with different temporal lobe structures.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
13 10 2020
13 10 2020
Historique:
received:
07
12
2019
accepted:
03
09
2020
revised:
14
08
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Recent studies examining electroconvulsive therapy (ECT) have reported that early sessions can induce rapid antidepressant and antipsychotic effects, and the early termination of ECT was reported to increase the risk of relapse. We hypothesized that different neural mechanisms associated with the therapeutic effects of ECT may be involved in the different responses observed during the early and late periods of ECT treatment. We investigated whether these antidepressant and antipsychotic effects were associated with temporally and spatially different regional gray matter volume (GMV) changes during ECT. Fourteen patients with major depressive disorder, with or without psychotic features, underwent 3-Tesla structural magnetic resonance imaging scans before (time point [Tp] 1), after the fifth or sixth ECT session (Tp2), and after ECT completion (Tp3). We investigated the regions in which GMV changed between Tp1 and Tp2, Tp2 and Tp3, and Tp1 and Tp3 using voxel-based morphometry. In addition, we investigated the association between regional GMV changes and improvement in depressive or psychotic symptoms. GMV increase in the left superior and inferior temporal gyrus during Tp1-Tp2 was associated with improvement in psychotic symptoms (P < 0.025). GMV increase in the left hippocampus was associated with improvement of depressive symptoms in Tp2-Tp3 (P < 0.05). Our findings suggest that different temporal lobe structures are associated with early antipsychotic and late antidepressant effects of ECT.
Identifiants
pubmed: 33051437
doi: 10.1038/s41398-020-01025-8
pii: 10.1038/s41398-020-01025-8
pmc: PMC7553938
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
344Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : JP26461743
Pays : International
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 17H04248
Pays : International
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18H05130
Pays : International
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 16H06572
Pays : International
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 20dm0307102h0002
Pays : International
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 20dm0307008h0003
Pays : International
Références
Transl Psychiatry. 2017 Feb 7;7(2):e1023
pubmed: 28170003
J Neurosci. 2000 Dec 15;20(24):9104-10
pubmed: 11124987
Neuroimage. 2009 Jan 1;44(1):83-98
pubmed: 18501637
Am J Psychiatry. 2004 Sep;161(9):1603-11
pubmed: 15337650
J Psychiatry Neurosci. 2016 Mar;41(2):105-14
pubmed: 26395813
Biol Psychiatry. 2020 Mar 1;87(5):451-461
pubmed: 31561859
Transl Psychiatry. 2014 Nov 18;4:e483
pubmed: 25405780
J Clin Psychiatry. 2004 Apr;65(4):485-91
pubmed: 15119910
Biol Psychiatry. 2000 Jun 15;47(12):1043-9
pubmed: 10862803
PLoS One. 2011;6(10):e26610
pubmed: 22028923
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1156-61
pubmed: 24379394
Front Hum Neurosci. 2012 Jun 22;6:180
pubmed: 22737114
J ECT. 2018 Jun;34(2):117-123
pubmed: 29389676
Acta Psychiatr Scand. 2014 Apr;129(4):303-11
pubmed: 23745780
J Affect Disord. 2015 Nov 1;186:186-91
pubmed: 26247910
Transl Psychiatry. 2016 Jun 07;6(6):e832
pubmed: 27271858
Br J Psychiatry. 2018 Feb;212(2):71-80
pubmed: 29436330
Acta Psychiatr Scand. 2018 Sep;138(3):180-195
pubmed: 29707778
Biol Psychiatry. 2016 Feb 15;79(4):282-92
pubmed: 25842202
Biol Psychiatry. 2004 Feb 1;55(3):301-12
pubmed: 14744473
Convuls Ther. 1996 Sep;12(3):138-46
pubmed: 8872401
Transl Psychiatry. 2016 Aug 23;6(8):e874
pubmed: 27552587
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
pubmed: 10860804
Eur Neuropsychopharmacol. 2016 Mar;26(3):506-17
pubmed: 26792445
Mol Psychiatry. 2017 Oct;22(10):1455-1463
pubmed: 27217146
Br J Psychiatry. 2018 Jan;212(1):19-26
pubmed: 29433612
Mol Psychiatry. 2020 Jul;25(7):1559-1568
pubmed: 30867562
J ECT. 2001 Dec;17(4):244-53
pubmed: 11731725
Schizophr Bull. 2012 Nov;38(6):1297-307
pubmed: 22080494
Biol Psychiatry. 2018 Oct 15;84(8):574-581
pubmed: 30006199
Lancet. 2003 Mar 8;361(9360):799-808
pubmed: 12642045
Neurosci Biobehav Rev. 2014 Jan;38:173-92
pubmed: 24300695
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Arch Gen Psychiatry. 2000 May;57(5):425-34
pubmed: 10807482
Trends Neurosci. 2013 May;36(5):259-67
pubmed: 23380665
Neuropsychopharmacology. 2019 Sep;44(10):1805-1811
pubmed: 30622299
Arch Gen Psychiatry. 2003 Nov;60(11):1069-77
pubmed: 14609882